{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ENTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-09T04:44:59.419Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1369,"canonical_name":"Entera Bio Ltd.","cik":"0001638097","uei":null,"lei":null,"duns":null,"ticker":"ENTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":19},"count":19,"timeline":[{"ts":"2026-07-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Entera Bio Ltd. — 2026-07-16","url_slug":"/sec/cik-0001638097/8-k/0001178913-26-003510","accession_number":"0001178913-26-003510","importance":35},{"ts":"2026-07-16","kind":"sec.filing","form_type":"4","title":"4 — Entera Bio Ltd. — 2026-07-16","url_slug":"/sec/cik-0001638097/4/0001178913-26-003508","accession_number":"0001178913-26-003508","importance":30},{"ts":"2026-07-14","kind":"sec.insider.a","reporter":"Toledano Miranda Jayne","title":"Chief Executive Officer","shares":347567,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares, par value NIS 0.0000769 per share","importance":15},{"ts":"2026-07-14","kind":"sec.insider.a","reporter":"Toledano Miranda Jayne","title":"Chief Executive Officer","shares":72993,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares, par value NIS 0.0000769 per share","importance":15},{"ts":"2026-06-03","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Entera Bio Ltd. — 2026-06-03","url_slug":"/sec/cik-0001638097/def-14a/0001178913-26-003077","accession_number":"0001178913-26-003077","importance":40},{"ts":"2026-06-03","kind":"sec.filing","form_type":"ARS","title":"ARS — Entera Bio Ltd. — 2026-06-03","url_slug":"/sec/cik-0001638097/ars/0001178913-26-003079","accession_number":"0001178913-26-003079","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Entera Bio Ltd. — 2026-06-03","url_slug":"/sec/cik-0001638097/defa14a/0001178913-26-003081","accession_number":"0001178913-26-003081","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"424B3","title":"424B3 — Entera Bio Ltd. — 2026-05-15","url_slug":"/sec/cik-0001638097/424b3/0001178913-26-002735","accession_number":"0001178913-26-002735","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Entera Bio Ltd. — 2026-05-15","url_slug":"/sec/cik-0001638097/effect/9999999995-26-001673","accession_number":"9999999995-26-001673","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"PRE 14A","title":"PRE 14A — Entera Bio Ltd. — 2026-05-14","url_slug":"/sec/cik-0001638097/pre-14a/0001178913-26-002703","accession_number":"0001178913-26-002703","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/10-q/0001178913-26-002458","accession_number":"0001178913-26-002458","importance":45},{"ts":"2026-05-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/8-k/0001178913-26-002455","accession_number":"0001178913-26-002455","importance":35},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/4/0001178913-26-002462","accession_number":"0001178913-26-002462","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/4/0001178913-26-002464","accession_number":"0001178913-26-002464","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/4/0001178913-26-002466","accession_number":"0001178913-26-002466","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"S-3","title":"S-3 — Entera Bio Ltd. — 2026-05-08","url_slug":"/sec/cik-0001638097/s-3/0001178913-26-002460","accession_number":"0001178913-26-002460","importance":30},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"Yaacov-Garbeli Dana","title":"Chief Financial Officer","shares":58394,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares, par value NIS 0.0000769 per share","importance":15},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"Burshtein Gregory","title":"Chief of R&D","shares":87591,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares, par value NIS 0.0000769 per share","importance":15},{"ts":"2026-05-07","kind":"sec.insider.a","reporter":"Galitzer Hillel","title":"Chief Operating Officer","shares":72993,"price_per_share":0,"usd_value":0,"security_title":"Ordinary Shares, par value NIS 0.0000769 per share","importance":15}]}